South Korean health authorities are set to decide on Sunday whether to resume the AstraZeneca vaccine rollout.
This comes one day after the authorities suspended the rollout for school nurses over safety concerns caused by possible links between blood clots and the AstraZeneca vaccine.
That stage of the rollout was supposed to start on Thursday.
"We will consider the vaccine's safety and scientific evidence prior to vaccinations. As we stopped vaccinations as a precautionary measure, we will gather experts' perspectives and suggest safe and scientific results for future vaccination campaigns."
This announcement came after the European Medicines Agency, on Wednesday, local time, concluded that blood clotting should be listed as a "very rare" side effect of the AstraZeneca vaccine, after finding a possible link between the two.
"Our safety committee, the Pharmacovigilance and Risk Assessment Committee of the European Medicines Agency, has confirmed that the benefits of the AstraZeneca vaccine in preventing COVID-19 overall outweigh the risks of side effects."
Meanwhile, the UK government changed the age limit for the use of the AstraZeneca vaccine now recommending alternative COVID-19 vaccines like Moderna and Pfizer for those under 30.
Following the EMA and UK assessments several European countries like Spain and Italy urged the use of the AstraZeneca vaccine only for people over 60, and Belgium has set its age limit as 55 and above.
In South Korea, another 35-thousand people got their first vaccine doses.
The country has so far given more than one million first doses covering slightly more than 2 percent of the population in the 41 days since the nationwide inoculation program started.
The vast majority were given the AstraZeneca vaccine.
About 170-thousand have had their first dose of the Pfizer vaccine, and 42-thousand people have received their first and second dose.
With an additional 94 cases of post-vaccination side-effects reported on Thursday a total of over 11-thousand people have reported side-effects from the vaccines.
Choi Won-jong, Arirang News.